Zübeyde Nur Özkurt

Zübeyde Nur Özkurt

Auto-generated profile, based on publicly available information

Zübeyde Nur Özkurt

Gazi University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
RHRauf Haznedar
Rauf Haznedar
SASahika Z. Akı
Sahika Z. Akı
ÜAÜmit Özgür Akdemir
Ümit Özgür Akdemir
ZÖZübeyde N. Özkurt
Zübeyde N. Özkurt
ÖÇÖzcan Çeneli
Özcan Çeneli
MÜMustafa Ünlü
Mustafa Ünlü

18 April 2019 in Leukemia & Lymphoma
Verified
Journal Article
Open access
ECEline M.P. Cremers
Eline M.P. Cremers
TWTheo de Witte
Theo de Witte
LWLiesbeth de Wreede
Liesbeth de Wreede
DEDiderik-Jan Eikema
Diderik-Jan Eikema
LKLinda Koster
Linda Koster
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger
Most myelodysplastic syndromes (MDS)-patients receive multiple red blood cell transfusions (RBCT). Transfusions may cause iron-related toxicity and mortality, influencing outcome after allogeneic HSCT. This prospective non-interventional study evaluated 222 MDS and CMML patients undergoing HSCT. Overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse incidence (RI) at 36 months were 52%, 44%, 25%, and 31%, respectively. Age, percentage of marrow blasts and severe comorbidities impacted OS. RFS was significantly associated with RBCT burden prior to HSCT (HR: 1.7; p = .02). High ferritin levels had a significant negative impact on OS and RI, but no impact on NRM. Administration of iron chelation therapy prior to HSCT did not influence the outcome, but early iron reduction after HSCT (started before 6 months) improved RFS significantly after transplantation (56% in the control group vs. 90% in the treated group, respectively; p = .04). This study illustrates the impact of RBCT and related parameters on HSCT-outcome. Patients with an expected prolonged survival after transplantation may benefit from early iron reduction therapy after transplantation.

25 June 2021 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
OAOlga Meltem Akay
Olga Meltem Akay
MOMurat Ozbalak
Murat Ozbalak
MPMustafa Pehlivan
Mustafa Pehlivan
BYBirol Yildiz
Birol Yildiz
AUAnt Uzay
Ant Uzay
BFBurhan Ferhanoglu
Burhan Ferhanoglu

24 February 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
GSGuldane Cengiz Seval
Guldane Cengiz Seval
IYIpek Yonal-Hindilerden
Ipek Yonal-Hindilerden
FHFehmi Hindilerden
Fehmi Hindilerden
NANeslihan Andıç
Neslihan Andıç
GÖGüner Hayri Özsan
Güner Hayri Özsan
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.

1 January 2021 in Hematology
Verified
Journal Article
Open access
TBTuğba Barlas
Tuğba Barlas
KIKamil Inci
Kamil Inci
GAGulbin Aygencel
Gulbin Aygencel
MTMelda Türkoğlu
Melda Türkoğlu
ÖTÖzlem Güzel Tunçcan
Özlem Güzel Tunçcan
MYMünci Yağcı
Münci Yağcı
The aim of this study was to investigate the data of HSCT patients who were admitted to our Hematology ICU due to infections or infectious complications.HSCT patients who were admitted to our Hemat...

23 January 2017 in Cancer Investigation
Verified
Journal Article
Closed access
ZÖZübeyde Nur Özkurt
Zübeyde Nur Özkurt
GSGülsan Türköz Sucak
Gülsan Türköz Sucak
ŞAŞahika Zeynep Akı
Şahika Zeynep Akı
MYMünci Yağcı
Münci Yağcı
RHRauf Haznedar
Rauf Haznedar
We hypothesized the levels of free light chains obtained before and after autologous stem cell transplantation can be useful in predicting transplantation outcome. We analyzed 70 multiple myeloma patients. Abnormal free light chain ratios before stem cell transplantation were found to be associated early progression, although without any impact on overall survival. At day +30, the normalization of levels of involved free light chain related with early progression. According to these results almost one-third reduction of free light chain levels can predict favorable prognosis after autologous stem cell transplantation.